抄録
In 95% of patients with pancreatic ductal adenocarcinoma, recurrence is observed following chemotherapy. Findings from several studies have indicated that cancer stem cells (CSCs) are resistant to anticancer agents and may be involved in cancer recurrence and metastasis. The CD44 protein is a major CSC marker, and CD44 also plays an indispensable role in the CSC properties in several cancers, including pancreatic cancer; however, no clinical approach exists to inhibit CD44 activity. Here, we have performed knock-in/knockdown experiments, and we demonstrate that the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/AMP-activated protein kinase/peroxisome proliferator-activated receptor-γ co-activator-1β (PGC-1β)/pyruvate dehydrogenase-A1 pathway is essential for CD44 expression and CSC properties. We observed that patients exhibiting high pyruvate dehydrogenase-A1 expression have a poor prognosis. Systemic PGC-1β knock-out mice are fertile and viable and do not exhibit an overt phenotype under normal conditions. This suggests that cGMP induction and PGC-1β inhibition represent potential strategies for treating patients with pancreatic ductal adenocarcinoma.
元の言語 | 英語 |
---|---|
ページ(範囲) | 10813-10823 |
ページ数 | 11 |
ジャーナル | Journal of Biological Chemistry |
巻 | 292 |
発行部数 | 26 |
DOI | |
出版物ステータス | 出版済み - 1 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biochemistry
- Molecular Biology
- Cell Biology
これを引用
The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. / Kumazoe, Motofumi; Takai, Mika; Hiroi, Shun; Takeuchi, Chieri; Kadomatsu, Mai; Nojiri, Takashi; Onda, Hiroaki; Bae, Jaehoon; Huang, Yuhui; Takamatsu, Kanako; Yamashita, Shuya; Kangawa, Kenji; Tachibana, Hirofumi.
:: Journal of Biological Chemistry, 巻 292, 番号 26, 01.01.2017, p. 10813-10823.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma
AU - Kumazoe, Motofumi
AU - Takai, Mika
AU - Hiroi, Shun
AU - Takeuchi, Chieri
AU - Kadomatsu, Mai
AU - Nojiri, Takashi
AU - Onda, Hiroaki
AU - Bae, Jaehoon
AU - Huang, Yuhui
AU - Takamatsu, Kanako
AU - Yamashita, Shuya
AU - Kangawa, Kenji
AU - Tachibana, Hirofumi
PY - 2017/1/1
Y1 - 2017/1/1
N2 - In 95% of patients with pancreatic ductal adenocarcinoma, recurrence is observed following chemotherapy. Findings from several studies have indicated that cancer stem cells (CSCs) are resistant to anticancer agents and may be involved in cancer recurrence and metastasis. The CD44 protein is a major CSC marker, and CD44 also plays an indispensable role in the CSC properties in several cancers, including pancreatic cancer; however, no clinical approach exists to inhibit CD44 activity. Here, we have performed knock-in/knockdown experiments, and we demonstrate that the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/AMP-activated protein kinase/peroxisome proliferator-activated receptor-γ co-activator-1β (PGC-1β)/pyruvate dehydrogenase-A1 pathway is essential for CD44 expression and CSC properties. We observed that patients exhibiting high pyruvate dehydrogenase-A1 expression have a poor prognosis. Systemic PGC-1β knock-out mice are fertile and viable and do not exhibit an overt phenotype under normal conditions. This suggests that cGMP induction and PGC-1β inhibition represent potential strategies for treating patients with pancreatic ductal adenocarcinoma.
AB - In 95% of patients with pancreatic ductal adenocarcinoma, recurrence is observed following chemotherapy. Findings from several studies have indicated that cancer stem cells (CSCs) are resistant to anticancer agents and may be involved in cancer recurrence and metastasis. The CD44 protein is a major CSC marker, and CD44 also plays an indispensable role in the CSC properties in several cancers, including pancreatic cancer; however, no clinical approach exists to inhibit CD44 activity. Here, we have performed knock-in/knockdown experiments, and we demonstrate that the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/AMP-activated protein kinase/peroxisome proliferator-activated receptor-γ co-activator-1β (PGC-1β)/pyruvate dehydrogenase-A1 pathway is essential for CD44 expression and CSC properties. We observed that patients exhibiting high pyruvate dehydrogenase-A1 expression have a poor prognosis. Systemic PGC-1β knock-out mice are fertile and viable and do not exhibit an overt phenotype under normal conditions. This suggests that cGMP induction and PGC-1β inhibition represent potential strategies for treating patients with pancreatic ductal adenocarcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85021682258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021682258&partnerID=8YFLogxK
U2 - 10.1074/jbc.M116.772111
DO - 10.1074/jbc.M116.772111
M3 - Article
C2 - 28507102
AN - SCOPUS:85021682258
VL - 292
SP - 10813
EP - 10823
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
SN - 0021-9258
IS - 26
ER -